Peptide drug conjugates hold a promising stance in the delivery of therapeutic agents by providing distinct advantage of improving therapeutic potential of drugs. But attempts to get the desired new drug doesn't succeed in each trial. So can anyone elaborate the challenges facing peptide drug bioconjugation. Thanks!
Last edited by catheymiller on Wed Nov 22, 2017 8:51 pm, edited 2 times in total.